Search

Your search keyword '"Ghandili, Susanne"' showing total 47 results
Start Over Author "Ghandili, Susanne"
47 results on '"Ghandili, Susanne"'

2. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations

Author

Shumilov, Evgenii, Mazzeo, Paolo, Ghandili, Susanne, Künstner, Axel, Weidemann, Sören, Banz, Yara, Ströbel, Philipp, Pollak, Matthias, Kolloch, Lina, Beltraminelli, Helmut, Kerkhoff, Andrea, Mikesch, Jan-Henrik, Schliemann, Christoph, Haase, Detlef, Wulf, Gerald, Legros, Myriam, Lenz, Georg, Feldmeyer, Laurence, Pabst, Thomas, Witte, Hanno, Gebauer, Niklas, and Bacher, Ulrike

Published
2024
Full Text
View/download PDF

5. Minimizing Long-Term Toxicities for Patients with Primary Mediastinal B-Cell Lymphoma Undergoing Modern Radiotherapy: Results from a Monocentric Biophysical Risk Evaluation.

Author

Baehr, Andrea, Schäfer, Sebastian, Jäckel, Maria, Becker, Saskia Alexandra, Ghandili, Susanne, Grohmann, Maximilian, Eich, Hans Theodor, and Oertel, Michael

Subjects
RISK assessment, RADIOTHERAPY, RADIATION injuries, HEART, LUNGS, MEDIASTINAL tumors, LONGITUDINAL method, RADIATION doses, B cell lymphoma, ESOPHAGUS, DISEASE risk factors
Abstract

Simple Summary: For young patients with the rare entity primary mediastinal B-cell lymphoma, a differentiated description of effects and side effects of the different therapeutic opportunities is of immense interest. We therefore conducted a planning study to compare two different radiation therapy planning variants for a cohort of these patients who were treated in a hospital cancer center. We estimated normal tissue complication probabilities for radiation side effects for the heart, the lungs and the esophagus. Introduction: Primary mediastinal B-cell lymphoma (PMBCL) is a rare form of aggressive B-cell lymphoma with a predominant onset in young patients. The minimization of potential (late) side effects is of cardinal interest for these patients. An anticipation of the individual risk profile is desirable to counsel the patient on the putative impact of radiotherapy (RT). Methods: RT plans for a cohort of 25 patients with PMBCL were prospectively designed. One plan with two parallel- opposing fields (APPA) and another with volume-modulated arc therapy (VMAT) technique with 40 Gy in 2 Gy fractions each. Normal The normal tissue complication probability (NTCP) was calculated using the Lyman-–Kutcher-–Burman model for heart, lung and oesophageal toxicity. Results: APPA planning resulted in lower median doses (Dmedian) for the heart and lungs, whereas all other dose metrics for heart, lungs and esophagus were lower in VMAT planning. A significant difference in the mean NTCPs when comparing the APPA to VMAT plans was seen for increased cardiac mortality, pneumonitis and esophagitis. PTV size correlated with increased cardiac mortality and esophagitis in both plan variations and with pneumonitis for VMAT plans. Dmean, Dmedian, and V20Gy correlated with the risk for pneumonitis, and Dmean, Dmedian, and V1% with the risk for esophagitis in both variants. Conclusions: We showed decreased risk of different NTCPs for VMAT and APPA planning for thoracic toxicities. The use of an IMRT technique like VMAT showed advantages for several DVH metrics in organs at risk and should therefore be recommended for radiation treatment of PMBCL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine

Author

Klingler, Felix, primary, Alsdorf, Winfried H., additional, Ghandili, Susanne, additional, Wolschke, Christine, additional, Brauneck, Franziska, additional, Bokemeyer, Carsten, additional, Fiedler, Walter, additional, Modemann, Franziska, additional, and Karagiannis, Panagiotis, additional

Published
2022
Full Text
View/download PDF

25. Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study

Author

Schönlein, Martin, Wrage, Victoria, Ghandili, Susanne, Mellinghoff, Sibylle C., Brehm, Thomas Theo, Leypoldt, Lisa B., Utz, Nils, Schrader, Roland M., Alsdorf, Winfried, Börschel, Niklas, Bußmann, Lara, Schönrock, Martin, Perlick, Dorothea, Schön, Gerhard, Verpoort, Karl, Lütgehetmann, Marc, Schulze zur Wiesch, Julian, Weisel, Katja C., Bokemeyer, Carsten, Schafhausen, Philippe, and Sinn, Marianne

Published
2022
Full Text
View/download PDF

26. Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study

Author

Schoenlein, Martin, Wrage, Victoria, Ghandili, Susanne, Mellinghoff, Sibylle C., Brehm, Thomas Theo, Leypoldt, Lisa B., Utz, Nils, Schrader, Roland M., Alsdorf, Winfried, Boerschel, Niklas, Bussmann, Lara, Schoenrock, Martin, Perlick, Dorothea, Schoen, Gerhard, Verpoort, Karl, Luetgehetmann, Marc, zur Wiesch, Julian Schulze, Weisel, Katja C., Bokemeyer, Carsten, Schafhausen, Philippe, Sinn, Marianne, Schoenlein, Martin, Wrage, Victoria, Ghandili, Susanne, Mellinghoff, Sibylle C., Brehm, Thomas Theo, Leypoldt, Lisa B., Utz, Nils, Schrader, Roland M., Alsdorf, Winfried, Boerschel, Niklas, Bussmann, Lara, Schoenrock, Martin, Perlick, Dorothea, Schoen, Gerhard, Verpoort, Karl, Luetgehetmann, Marc, zur Wiesch, Julian Schulze, Weisel, Katja C., Bokemeyer, Carsten, Schafhausen, Philippe, and Sinn, Marianne

Published
2022

27. Clinical features of hepatitis E infections in patients with hematologic disorders

Author

Ghandili, Susanne, primary, Lindhauer, Cecilia, additional, Pischke, Sven, additional, Zur Wiesch, Julian Schulze, additional, Von Kroge, Philipp H., additional, Polywka, Susanne, additional, Bokemeyer, Carsten, additional, Fiedler, Walter, additional, Kröger, Nicolaus, additional, Ayuk, Francis, additional, Adjallé, Raissa, additional, and Modemann, Franziska, additional

Published
2022
Full Text
View/download PDF

29. Donor‐transmitted extramedullary acute myeloid leukaemia after living donor kidney transplantation

Author

Ghandili, Susanne, primary, Kluger, Malte A., additional, Leitner, Theo, additional, Grahammer, Florian, additional, Kirchner, Lennart, additional, Modemann, Franziska, additional, Achilles, Eike‐Gert, additional, Kreipe, Hans H., additional, Klein, Janin, additional, Steinemann, Doris, additional, Wolschke, Christine, additional, Fischer, Lutz, additional, Bokemeyer, Carsten, additional, Fiedler, Walter, additional, Huber, Tobias B., additional, Alsdorf, Winfried H., additional, and Mahmud, Maida, additional

Published
2022
Full Text
View/download PDF

31. Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma

Author

Ghandili, Susanne, primary, Schönlein, Martin, additional, Wiessner, Christian, additional, Becher, Heiko, additional, Lütgehetmann, Marc, additional, Brehm, Thomas Theo, additional, Schulze zur Wiesch, Julian, additional, Bokemeyer, Carsten, additional, Sinn, Marianne, additional, Weisel, Katja C., additional, and Leypoldt, Lisa B., additional

Published
2021
Full Text
View/download PDF

35. OAB-049: Poor post-vaccination anti-SARS-CoV-2-antibody response in patients with Multiple Myeloma correlates with low CD19+ B-lymphocyte count and anti-CD38 treatment

Author

Ghandili, Susanne, primary, Schönlein, Martin, additional, Lütgehetmann, Marc, additional, Wiesch, Julian Schulze zur, additional, Becher, Heiko, additional, Bokemeyer, Carsten, additional, Sinn, Marianne, additional, Weisel, Katja, additional, and Leypoldt, Lisa, additional

Published
2021
Full Text
View/download PDF

39. Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients

Author

Ghandili, Susanne, primary, Pfefferle, Susanne, additional, Roedl, Kevin, additional, Sonnemann, Piet, additional, Karagiannis, Panagiotis, additional, Boenisch, Olaf, additional, Kluge, Stefan, additional, Schmiedel, Stefan, additional, Ittrich, Harald, additional, Rohde, Holger, additional, Lütgehetmann, Marc, additional, Weisel, Katja, additional, Bokemeyer, Carsten, additional, Wichmann, Dominic, additional, Fiedler, Walter, additional, Jarczak, Dominik, additional, and Modemann, Franziska, additional

Published
2020
Full Text
View/download PDF

40. Integrative public data-mining pipeline for the validation of novel independent prognostic biomarkers for lung adenocarcinoma

Author

Ghandili, Susanne, primary, Oqueka, Tim, additional, Schmitz, Melanie, additional, Janning, Melanie, additional, Körbelin, Jakob, additional, Westphalen, C Benedikt, additional, P Haen, Sebastian, additional, Loges, Sonja, additional, Bokemeyer, Carsten, additional, Klose, Hans, additional, and K Hennigs, Jan, additional

Published
2020
Full Text
View/download PDF

41. COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies.

Author

Modemann, Franziska, Niederwieser, Christian, Weisel, Katja, Bokemeyer, Carsten, Fiedler, Walter, and Ghandili, Susanne

Subjects
INFLUENZA, SEASONAL influenza, HEMATOLOGIC malignancies, ADULT respiratory distress syndrome, STEM cell transplantation, COVID-19
Abstract

The severity and mortality of COVID-19 and seasonal influenza were recently compared in the general population but not in patients with hematological malignancies. We analyzed the clinical courses of 79 patients with hematological malignancies and diagnosis of either SARS-CoV-2 (n = 29) or influenza A or B infections (n = 50) who were admitted or were already under treatment in the Department of Oncology, Hematology and Stem cell Transplantation at the University Medical Center Hamburg-Eppendorf, Germany, between 1 January 2012 and 31 January 2021. For COVID-19, we observed significantly higher rates of acute respiratory distress syndrome with 48% (14/29) compared to 14% (7/50) in the influenza group (p = 0.001) as well as a significantly higher virus-associated 90-day mortality (41% vs. 12%, p = 0.005). Based on our results, we conclude that infections with SARS-CoV-2 are more severe than influenza A or B in patients with hematological malignancies. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

46. Therapy of necrobiotic xanthogranuloma - case series and review of the literature.

Author

Hansen I, Ghandili S, Abeck F, Booken N, and Schneider SW

Subjects
Humans, Chlorambucil, Necrobiotic Xanthogranuloma diagnosis, Necrobiotic Xanthogranuloma therapy, Paraproteinemias complications, Paraproteinemias pathology, Skin Diseases pathology, Histiocytosis, Non-Langerhans-Cell
Abstract

Necrobiotic xanthogranuloma is a rare disease that is part of the non-Langerhans cell histiocytoses. It is characterized by yellowish skin lesions, which are typically periorbitally localized. Extracutaneous manifestations of all organs are possible and can cause potentially life-threatening complications. The disease also belongs to the facultative paraneoplasias and is often associated with paraproteinemia. These aspects should be considered regarding further diagnostics. Due to the rarity of the disease, there are no standardized guidelines for therapy so far. The combination of prednisolone and chlorambucil as well as intravenous immunoglobulins seem to be effective therapeutic options. We present four cases from our clinic as well as the current results of the literature in this mini-review and would like to highlight the therapeutic challenge as well as the need for the development of guidelines., (© 2023 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results